|
|
Vaccine Detail
|
LVRNA009 |
| Vaccine Information |
- Vaccine Name: LVRNA009
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: AIM Vaccine Co., Ltd.
- Vaccine Ontology ID: VO_0005414
- Type: mRNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
- Description: Phase I: NCT05364047
Phase II: NCT05352867
|
| Host Response |
|
Mouse Response
- Immune Response: serum samples from mice immunized with monovalent Delta vaccine showed relatively low virus neutralization titers (VNTs) against the pseudotyped virus of the Omicron strains. Serum samples from mice immunized with bivalent Delta/BA.1 vaccine had high VNTs against the pseudotyped Wuhan-Hu-1, Delta, and BA.1 strains but low VNTs against BA.2 and BA.5 (p < 0.05). Serum samples from mice immunized with Delta/BA.2 vaccine had high VNTs against the pseudotyped Wuhan-Hu-1, Delta, BA.1 and BA.2 strains but low VNTs against BA.5. Finally, serum samples from mice immunized with Delta/BA.5 vaccine had high VNTs against all the tested pseudotyped SARS-CoV-2 strains including the Wuhan-Hu-1, Delta, and Omicron variants (p > 0.05).(Li et al., 2022)
|
| References |
Li et al.,: Jianglong Li, Qi Liu, Jun Liu, Zihui Fang, Liping Luo,, Shuang Li, Yixin Lei, Zhi Li, Jing Jin, Ronglin Xie, Yucai Peng. Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. . 2022; ; . [PubMed: 36366316].
|
|
